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Abstract
Background: Pulsatile GnRH therapy is the gold standard treatment for ovulation induction in women having
functional hypothalamic amenorrhea (FHA). The use of pulsatile GnRH therapy in FHA patients with polycystic
ovarian morphology (PCOM), called “FHA-PCOM”, has been little studied in the literature and results remain
contradictory. The aim of this study was to compare the outcomes of pulsatile GnRH therapy for ovulation
induction between FHA and “FHA-PCOM” patients in order to search for an eventual impact of PCOM.
Methods: Retrospective study from August 2002 to June 2015, including 27 patients with FHA and 40 “FHA-PCOM”
patients (85 and 104 initiated cycles, respectively) treated by pulsatile GnRH therapy for induction ovulation.
Results: The two groups were similar except for markers of PCOM (follicle number per ovary, serum Anti-Müllerian
Hormone level and ovarian area), which were significantly higher in patients with “FHA-PCOM”. There was no
significant difference between the groups concerning the ovarian response: with equivalent doses of GnRH, both
groups had similar ovulation (80.8 vs 77.7 %, NS) and excessive response rates (12.5 vs 10.6 %, NS). There was no
significant difference in on-going pregnancy rates (26.9 vs 20 % per initiated cycle, NS), as well as in miscarriage,
multiple pregnancy or biochemical pregnancy rates.
Conclusion: Pulsatile GnRH seems to be a successful and safe method for ovulation induction in “FHA-PCOM”
patients. If results were confirmed by prospective studies, GnRH therapy could therefore become a first-line
treatment for this specific population, just as it is for women with FHA without PCOM.
Keywords: Functional hypothalamic amenorrhea, Polycystic ovarian morphology, Pulsatile GnRH therapy, Excessive
ovarian response, Pregnancy
Background
Functional Hypothalamic Amenorrhea (FHA) is one of the
most common causes of secondary amenorrhea [1–3].
FHA is due to a chronic energy deprivation, mostly caused
by significant weight loss, severe food restriction and/or
excessive exercise. This negative energy balance leads to a
reduced frequency of the gonadotropin-releasing hormone
(GnRH) pulses, which is responsible for gonadotropin in-
sufficiency and results in anovulation and hypoestrogenism
[2]. It has been demonstrated that pulsatile GnRH therapy
is the best treatment to induce ovulation and pregnancy in
women with FHA [4, 5], but it is available in only few coun-
tries worldwide. In women with FHA, by restoring a GnRH
secretion and its pulsatility, this therapy results almost in
95 % pregnancy rate in 6 months [6, 7].
Polycystic ovarian morphology (PCOM) is the third cri-
terion of the Rotterdam classification for Polycystic ovarian
syndrome (PCOS) [8, 9]. Its definition essentially lies on an
excessive number of antral follicles per ovary (FNPO) ≥ 12
and/or ovarian volume ≥ 10 mL [8, 10]. Pulsatile GnRH
therapy has been tried in women with PCOS but the results
remain mixed [11–13]. Neither the meta-analysis from the
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Cochrane Database [14], nor the Thessaloniki consensus
[15], recommends GnRH pulsatile therapy in PCOS.
Besides PCOS, PCOM may also be observed as an iso-
lated feature in about 30 % of normal women and in pa-
tients with FHA [16]. The association between FHA and
PCOM has been poorly described in the literature and the
studies are heterogeneous (variable diagnostic criteria for
FHA and PCOM, confusion between hypogonadotropic
hypogonadism and FHA, inconsistent LH level, small series
or case reports) and as a result, the conclusions are contra-
dictory [17–25]. More recently Dubourdieu et al. [26] have
demonstrated the superiority of pulsatile GnRH therapy
over gonadotropin, for ovulation induction in women with
‘FHA-PCOM’ (on-going pregnancy rates: 46.7 % versus
0 %; p = 0.02). However, this study has been restricted to
only one treatment cycle, with interestingly similar ovarian
responses in both groups.
It is therefore difficult to determine whether the presence
of PCOM modifies or not the results of pulsatile GnRH
therapy, when used for ovulation induction in women with
FHA. Some issues remain unanswered such as: is there a
higher risk of excessive ovarian response, of multi follicular
responses and finally of multiple pregnancies? Or on the
contrary, does the presence of PCOM make the stimulation
more difficult, with lower ovulation and on-going preg-
nancy rates?
The aim of this study was to compare the use of pulsa-
tile GnRH therapy for ovulation induction in patients with
FHA and in patients with “FHA-PCOM”, and to obviate
any possible impact of the presence of PCOM.
Methods
This is a retrospective study in which data were collected
from August 2002 to June 2015 in the Department of
Endocrine Gynaecology and Reproductive Medicine, Uni-
versity Hospital of Lille, France. All women included were
adults, wishing a pregnancy and presenting FHA only or
“FHA-PCOM”. The patients were stimulated for ovulation
induction with pulsatile GnRH therapy. This study was ap-
proved by the International Review Board of the University
of Lille and all patients had given consent for the use of
their clinical record.
Population
Patients’ data, including their medical background, history
of body weight, eating habits and the type and frequency of
sports activity, were collected. Age, size, weight (with recent
evolution) and body mass index were reported, as well as
signs of hypometabolism (fatigue, chilliness, coldness of the
body’s extremities, bradycardia, lanugo). All patients bene-
fited from a full psycho-nutritional support, in order to
identify any potential eating disorder. Patients with im-
portant eating disorders or metabolic complications were
excluded from the study as their condition contraindi-
cated pregnancy.
FHA was defined as secondary amenorrhea over
6 months, failure to bleed after progesterone with-
drawal test, in a context of low body weight (BMI < 18)
and/or history of important weight loss and/or intense
physical activity, leading to a negative energy balance.. As
FHA is a diagnosis of exclusion, every patient had a normal
pituitary magnetic resonance imaging, normal prolactin
and TSH levels and a non-elevated basal FSH level.
PCOM was defined by antral follicle excess on ultrasound
and/or high serum AMH level. The threshold was ≥ 12
FNPO until 2008, then ≥ 19 FNPO with new ultrasound
equipment (see below) [27]. Serum AMH level ≥ 35 pmol/L
was considered as a surrogate to the excessive FNPO [27].
Ovulation induction was then carried out provided that
the patient had a strictly normal hysterosalpingogram and
the partner, a normal semen analysis.
Exclusion criteria were tubal obstruction, endometriosis,
any other aetiology of central hypogonadism or sperm
abnormalities.
Assay and ultrasound procedures
For each patient, ultrasound and serum assays were per-
formed a week after a progesterone challenge test (dydro-
gesterone 10 mg/day for 10 days). Patients remained in
amenorrhea. Biological assessment included serums of
FSH, E2, LH, prolactin, TSH, FT4, FT3, testosterone, dehy-
droepiandrosterone sulfate (DHEAS), Delta-4-androstenedi
one and 17-hydroxyprogesterone, as described previously
[27–29]. Serum AMH levels were measured by ELISA
technique with a second generation immunoassay kit,
using monoclonal antibodies directed against the human
AMH, called AMH-MIS (Beckmann Coulter, Immuno-
tech Marseille, France), as previously described [27].
The ultrasound device used between 2002 and 2008 was
a Logic 400 General Electric Milwaukee, replaced in 2008
by a General Electric Voluson E8 (probe frequencies were
5–7 MHz and 5–13 MHz, respectively). All follicles be-
tween 2 to 9 mm were included in the assessment of AFC.
Treatment protocols
The GnRH pump (Lutrepulse®, Ferring, SAS, Gentilly,
France) was placed intravenously (IV) or subcutaneously
(SC) by the nurse of the department and was programmed
to deliver 1 pulse of GnRH every 90 min (gonadoréline,
Lutrelef® 3.2 mg, Ferring, SAS, Gentilly, France). The start-
ing dose was the standard 15 μg SC and 5 μg IV, then
adapted to the ovarian response.
The ovarian response was systematically controlled by
serum E2 and LH assays and pelvic ultrasound. The first
monitoring was made on the 8th day of the stimulation,
looking for multifollicular response and, if needed, treat-
ment was adapted: decreased in case of multifollicular
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response or increased if no response. Patients were mon-
itored under the same conditions until the emergence of
at least one dominant follicle. The response was consid-
ered as excessive if there were more than 2 dominant
follicles on ultrasound and/or E2 serum level ≥1835 pmol/
L [30], leading to the cancellation of the cycle. Monitoring
was ended once 1 or 2 dominant follicle(s) exceeded
13 mm in diameter. The pump remained in place until a
spontaneous ovulation, as indicated by a serum progester-
one assay (≥5 ng/mL) seven days after the presumed date
of ovulation.
The luteal phase support was provided by one injec-
tion of hCG 1500 IU every 3 days, starting on the day
of the withdrawal of the pump. A blood hCG pregnancy
test was carried out systematically 14 days after ovula-
tion. An ultrasound was performed around 6 or 7 weeks
of amenorrhea in order to control the localisation of
the pregnancy and its evolution, and to identify mul-
tiple pregnancies.
Statistics
Quantitative variables were expressed as mean with
standard deviation, or as median with 5th and 95th
percentiles, according to the Gaussian or non-Gaussian
distribution of the variables, respectively. To compare
the two groups, the student T-test or the non-
parametric Mann Whitney test was used, respectively.
Qualitative variables were expressed in percentages and
compared by a Chi2 or a Fisher test, according to the
size of the population. Results were considered signifi-
cant when p was < 0.05.
Results
Sixty-seven patients were included in the study: 27 in the
group “FHA” and 40 in the group “FHA-PCOM” (85 and
104 initiated cycles, respectively).
Both groups were similar except for the ultrasound aspect
of PCOM and for serum AMH levels, which were signifi-
cantly higher in “FHA-PCOM” patients (Table 1).
There was no significant difference concerning the
ovulation rate (80.8 vs 77.7 %, NS), the cancelled cycle
an excessive ovarian response rates (12.5 vs 10.6 %,
NS) (Table 2). The dose of GnRH was not different be-
tween the groups, either for the first cycle or the mean
of all cycles (Tables 2 and 4).
There was no significant difference concerning pregnancy
rates, whether it was per initiated cycle (26.9 vs 20.0 %, NS;
Table 2), or per ovulatory cycles (33.3 vs 28.5 %, NS;
Table 3) or per patient (70.0 vs 63.0 %, NS; Fig. 1).
There was no significant difference between FHA and
“FHA-PCOM” for biochemical pregnancy, miscarriage
and multiple pregnancy rates.
There was no difference between the 2 groups when
ovulatory cycles were compared (Table 4): same doses of
GnRH, same stimulation duration, equivalent monofolli-
cular response (78.6 vs 71.2 %, NS), and no more bifollicu-
lar reponse (20.2 vs 24.2 %, NS).
Discussion
This study shows that the groups were not different from
each other, except for PCOM features and serum AMH.
The gonadotropin insufficiency was therefore similar in our
patients with FHA only and with “FHA-PCOM”. Ovulation
induction with pulsatile GnRH therapy seemed to take
Table 1 Clinical, hormonal and ultrasound data
FHA PCOM
(n = 40)
FHA (n = 27) p
Age (years) 28.5 [25.0–35.0] 28 [25.0–32.7] NS
BMI (kg/m2) 18.5 [16.5–21.0] 18.1 [16.1–20.0] NS
Clinical hyperandrogenism (%) 7.5 % (n = 3) 14.8 % (n = 4) NS
LH (IU/L) 1.7 [0.5–3.9] 1.1 [0.5–3.6] NS
FSH (IU/L) 4.9 [2.4–8.7] 5 [3.7–8.2] NS
E2 (pmol/L) 80.7 [44.0–168.8] 73.4 [43.7–114.1] NS
AMH (pmol/L) 51.0 [19.9–95.7] 18.4 [8.5–28.5] <0,001
Follicle Number Per Ovary:
- before 2008 13.0 [7.5–19.3] 7.5 [3.0–10.0] <0,001
- after 2008 17.5 [9.8–41.0] 9.0 [3.0–14.3] <0,001
Ovarian area (cm2) 4.1 [2.3–5.8] 3.1 [1.5–4.8] <0,001
TESTOSTERONE (nmol/L) 0.7 [0.3–2.8] 0.7 [0.3–1.7] NS
DELTA 4 (nmol/L) 4.5 [2.1–9.4] 4.2 [2.4–7.7] NS
DHEAS (μmol/L) 3.4 [1.4–6.3] 3.4 [1.8–5.7] NS
Values are medians with [5th–95th] percentiles
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place exactly the same way in both groups. Indeed, the
doses of GnRH and the stimulation duration were equiva-
lent. Ovarian response also appeared to be identical in both
groups as there were the same monofollicular and bifollicu-
lar response rates. There was no more excessive ovarian
response in patients with “FHA-PCOM”. And there was no
difference between the two groups concerning on-going
pregnancy rates, as well as miscarriage, multiple pregnancy
and biochemical pregnancy rates.
The study observed about 20 % of bi-follicular response
with pulsatile GnRH therapy in both groups. However
and in agreement with the literature [4], the multiple
pregnancy rate reported was low. The risk of multiple
pregnancy is therefore not null, which imposes a fair
information to couples, and a careful monitoring
based on ultrasound and biology, rather than a simple
clinical monitoring, as recommended in some previ-
ous studies [31].
This study demonstrates that the presence of PCOM in
patients with FHA does not influence the management of
the pulsatile GnRH therapy, nor the ovarian response to
the treatment and the pregnancy rates. The pump appears
therefore to be as efficient in “FHA-PCOM’” patient as it
is in FHA patients [4]. This disagrees with previous stud-
ies [20, 22, 23] or case reports [17, 18], which showed the
revelation of true PCOS in patients with “FHA-PCOM”,
when treated with pulsatile GnRH therapy.
This study raises the question whether PCOM is actu-
ally indicative of a pre-existing but latent PCOS, “switched
off” because of the gonadotropin insufficiency, or simply
an ultrasound manifestation. The existence of PCOM is
quite frequent in general population, including normo-
ovulatory women with no hyperandrogenism [32–35]. In
FHA, Robin et al. [16] identified (by cluster analysis) 3
groups of patients, depending on serum AMH level (as a
surrogate for PCOM). The first two groups (normal serum
AMH level (52 %) and moderate increase (about two-fold)
of serum AMH level (38 %)) were in line with findings in
female controls. The third group (10 %) with significantly
higher serum AMH levels (about four-fold) was not found
in controls. This suggests that this third group could
match pre-existing PCOS “masked” by the gonadotropin
deficiency of the FHA and would correspond to the cases
reported by others [17, 20, 22, 23]. Our study is retro-
spective and cannot attest the revelation of true PCOS in
some of our “FHA-PCOM” patients. To do so, it would
be interesting to run a prospective trial and to systemat-
ically look for revelation of PCOS during the stimula-
tion (elevation of serum androgens levels, increased
number of follicles on ultrasound and/or serum AMH
level…) [36].






Ovulatory cycle rate 80.8 % (n = 84) 77.7 % (n = 66) NS
Cancelled cycles rate 19.2 % (n = 20) 22.4 % (n = 19) NS
- for excessive response 12.5 % (n = 13) 10.6 % (n = 9) NS
- for poor response 1.9 % (n = 2) 0 % (n = 0) NS
- for ovarian cyst 0 % (n = 0) 5.9 % (n = 5) NA
- other 4.8 % (n = 5) 5.9 % (n = 5) NS
Positive pregnancy test rate 32.7 % (n = 34) 24.7 % (n = 21) NS
Clinical pregnancy rate 28.8 % (n = 31) 23.5 % (n = 20) NS
Clinical ongoing pregnancy
rate
26.9 % (n = 28) 20.0 % (n = 17) NS
Miscarriage rate 2.9 % (n = 3) 3.5 % (n = 3) NS
Multiple pregnancy rate 1.0 % (n = 1) 2.4 % (n = 2) NS
Biochemical pregnancy
rate
2.9 % (n = 3) 1.2 % (n = 1) NS
Mean (+/− S.D) starting
doses of GnRH chosen
for the first cycle (μg):
- intravenous 4.9 (+/− 0.3) 5.3 (+/− 1.3) NS
- subcutaneous 12.0 (+/− 4.6) 15.0 (+/− 4.5) NS
Mean (+/− S.D) starting
doses
of GnRH (all cycles) (μg):
- intravenous 5.7 (+/− 2.1) 5.5 (+/− 2.1) NS
- subcutaneous 11.8 (+/− 4.9) 13.1 (+/− 6.3) NS






Positive pregnancy test rate 40.5 % (n = 34) 31.8 % (n = 21) NS
Clinical pregnancy rate 36.9 % (n = 31) 30.3 % (n = 20) NS
Clinical ongoing pregnancy rate 33.3 % (n = 28) 25.8 % (n = 17) NS
Miscarriage rate 3.6 % (n = 3) 4.6 % (n = 3) NS
Multiple pregnancy rate 1.2 % (n = 1) 3.0 % (n = 2) NS


























Fig. 1 Cumulative on-going pregnancy rates per initiated cycle for
FHA and FHA-PCOM patients
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The limitations of our study are mainly linked to its
retrospective design. Although it might be the largest sam-
ple of patients with “FHA-PCOM” (40 patients, 84 initiated
cycles), it remains a retrospective study with insufficient
methodology to recommend pulsatile GnRH therapy as
first-line treatment for ovulation induction. Also, the high
prevalence of “FHA-PCOM” patients in this series was
presumably due to a referral bias. Also, there are some
controversies about the definition of PCOM, which is com-
monly defined by an excessive FNPO ≥ 12. However, this
cut-off is highly dependent on ultrasound equipment and
operator skill. Therefore, with the latest ultrasound gener-
ation, Dewailly et al. [27] have proposed a new threshold of
19 FNPO. Similarly, a panel of international experts has
recently suggested a threshold of 25 follicles, when the
ultrasound probe provides a maximum frequency greater
that 8 MHz [37]. Serum AMH concentration is strongly
correlated with the FNPO since it is mostly secreted from
the small antral follicles from 2 to 9 mm, counted on ultra-
sound [37–40]. Dewailly et al. [27] have described a correl-
ation between FNPO and serum AMH and defined serum
AMH level ≥ 35 pmol/L as a surrogate for PCOM. How-
ever, this threshold was established with a specific centre
and whether it can be extrapolated to other centres (using
different control populations and AMH assays) still has to
be verified. Last, the cost of one ovulatory cycle remains
more expensive with the pump than with gonadotropins.
However, in another study (under submission), we have
compared the use of these two treatments for ovulation
induction in “FHA-PCOM” patients and we showed that it
was faster to induce a pregnancy with pulsatile GnRH ther-
apy. Indeed, the on-going pregnancy rate after one initiated
cycle of GnRH therapy was 28.9 %, while 3 subsequent
cycles of gonadotropins had to be initiated to reach a close
rate of 23.6 %. So, the total final cost for a pregnancy was
relatively close between pulsatile GnRH therapy (1643€)
and hMG (1421€), but much more expensive with recom-
binant gonadotropins (4334€). We did not take into ac-
count the costs of monitoring and blood samples (heavier
with gonadotropins) and of eventual hospitalization for
OHSS (more frequent with gonadotropins). As to the even-
tual discomfort of the pump, in our experience, most of the
patients did not consider that carrying the device was worse
than the daily injections of gonadotropins, where the stimu-
lation duration was significantly longer.
Conclusion
In conclusion, this study demonstrates that for ovulation
induction, pulsatile GnRH therapy yields as good results in
women having both FHA and PCOM as in women with
FHA only. Therefore the presence of PCOM should not
alter the management of FHA patients wishing a preg-
nancy. However, these findings need to be confirmed by
prospective studies in order to make pulsatile GnRH ther-
apy the first-line treatment for “FHA-PCOM” patients, just
as it is for patients with FHA only.
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